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Abstract: High-throughput metabolomics investigations, when conducted in large human cohorts,
represent a potentially powerful tool for elucidating the biochemical diversity underlying human
health and disease. Large-scale metabolomics data sources, generated using either targeted or
nontargeted platforms, are becoming more common. Appropriate statistical analysis of these complex
high-dimensional data will be critical for extracting meaningful results from such large-scale human
metabolomics studies. Therefore, we consider the statistical analytical approaches that have been
employed in prior human metabolomics studies. Based on the lessons learned and collective
experience to date in the field, we offer a step-by-step framework for pursuing statistical analyses
of cohort-based human metabolomics data, with a focus on feature selection. We discuss the range
of options and approaches that may be employed at each stage of data management, analysis, and
interpretation and offer guidance on the analytical decisions that need to be considered over the
course of implementing a data analysis workflow. Certain pervasive analytical challenges facing the
field warrant ongoing focused research. Addressing these challenges, particularly those related to
analyzing human metabolomics data, will allow for more standardization of as well as advances in
how research in the field is practiced. In turn, such major analytical advances will lead to substantial
improvements in the overall contributions of human metabolomics investigations.
Keywords: statistical methods; large-scale metabolomics; high-dimensional data
1. Introduction
Rapid advances in mass spectrometry (MS) technologies have enabled the generation of large-scale
metabolomics data in human studies. These technical advances have outpaced the development of
statistical methods for handling and analyzing datasets now of burgeoning size and complexity [1–3].
Early investigations using metabolomics technologies have applied a variety of statistical methods
in analyses of datasets containing up to 200 metabolite measures, typically acquired from a targeted
metabolomics platform collected from human studies involving tens to hundreds of observations [4,5].
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Nontargeted metabolomics platforms now allow the measurement of up to tens of thousands
of metabolites, most which are unknown molecular species that demonstrate varying levels of
intercorrelations within a given dataset as well as correlations with a given clinical outcome [6].
Furthermore, current metabolomics technologies have augmented throughput capacity that can facilitate
data collection for thousands of observations per human cohort experiment [7,8]. At present, however,
there are no existing standard protocols for analyzing these increasingly complex metabolomics data.
Thus, herein, we review the available statistical methods for analyzing high-dimensional metabolomics
data in the setting of a clinical study. We also outline an accessible yet flexible approach that can be
used to optimize sensitivity and specificity for identifying potentially important metabolites associated
with a clinically relevant outcome.
2. Analytical Challenges
Due to the increasing complexity of metabolomics data, combined with the variety of different
study designs employed in practice, customized approaches are often required for analyzing metabolite
variation in relation to clinical outcomes. Notwithstanding differences in study design and data
structure, common to almost all metabolomics datasets is the need to address certain statistical
considerations (Table 1). An initial key consideration is missingness, given that all metabolomic data
invariably demonstrate patterns of missing values that are often but not always more frequent for low
abundant metabolites. Contributing factors include underlying biology (e.g., very low or true zero
values due to biological differences between healthy and disease-enriched cohorts) and technical issues
(e.g., actual values below the detection limits for a given method, which may or may not be rectified
using different or complementary methods). The etiology of missing values will vary, at least in part,
based on the platform used to profile metabolites (i.e., nuclear magnetic resonance [NMR] spectroscopy,
gas chromatography mass spectrometry [GC-MS], liquid chromatography mass spectrometry [LC-MS]).
In rare circumstances, for certain types of metabolites (e.g., derivatives of known toxic exposures),
missing values may be most appropriately coded as true zero values as opposed to imputed. There is
some research on the best methods for dealing with missing data in the context of metabolomics [9–11].
The appropriate choice depends on whether the authors believe their data is missing at random (MAR)
or missing not at random (MNAR) [12]. Data that are MAR are missing due to observed factors that
can be modeled, while MNAR data would occur if the data are missing due to unobserved factors.
In metabolomics, MNAR can occur when data are missing because they are below the limit of detection.
If it is believed that data are missing due to limit of detection issues then users can impute the missing
values using quantile regression imputation of censored data (QRILC), which is available in the R
package imputeLCMD [13]. This was shown to outperform the standard approach of simply filling in
missing values with half the minimum observed value [9]. If users believe the data are MAR, then they
should be imputed using multiple imputation strategies. Recent studies have seen that both random
forest or k-nearest neighbors imputation work well [9,10]. Regardless of the imputation strategy used,
we recommend users impute the missing values as failing to do so can lead to underestimation of
standard errors and potentially biased estimates of effect of interest.
Table 1. Statistical considerations for human metabolomics data.
Consideration Notes and Examples
Missingness
Patterns of missing values tend to be non-random and are even sometimes predictable. For example,
missing values may often but not always be more frequent for metabolites that are intrinsically low
in abundance when measured from a given tissue type.
Missingness may be due to biological and/or technical reasons.
Data distributions
Many but not all metabolites tend to demonstrate right-skewed distributions in most types of
human studies (e.g., healthy controls or disease-specific referral samples).
Certain metabolites will display a substantial proportion of zero values that may be considered true
zero values based on biology (an issue to be considered along with but
distinguished from missingness).
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Table 1. Cont.
Consideration Notes and Examples
Intercorrelations
Intercorrelations between metabolites may well reflect clustering of small molecules by known or
(mostly) unknown biological pathways.
Intercorrelations will vary widely depending on a given exposure or background, chronic disease
status, and other yet unidentified factors.
Intercorrelations will also vary depending on the underlying mass spectrometry (MS) method used
to create a given dataset (i.e., nontargeted vs. targeted, and the specific technical methods used).
Time-dependence
Whereas a portion of the human metabolome changes dynamically in response to acute
perturbation or stress, many other metabolites display variation only over several days to weeks in
response to subacute perturbations; other portions of the metabolome may yet exhibit relatively
little change over time, except in response to major chronic exposures.
Confounding factors
Metabolite values will vary in response to factors that are measurable as well as factors that are not
easily measurable for a given study, such as acute and chronic dietary patterns, microbiota, and
environmental exposures.
For non-zero metabolite variables, transformation is usually recommended due to frequently
right-skewed distributions [14]. Bimodal or multimodal distributions may also be seen, albeit less
commonly. While many statistical approaches do not rely on the distribution of metabolites being
symmetric, transformation can help reduce the impact of outliers when the distribution is highly skewed.
Irrespective of distribution patterns, metabolite variables almost always demonstrate intercorrelations.
The extent to which intercorrelations exist between metabolites will vary between datasets due to
a variety of factors, including those related to study sampling as well as technical issues. Dealing
with correlations between metabolites depends on the scientific goal of the study. If the goal is to
predict the outcome given the metabolites, or to understand if any of the metabolites are predictive of
the outcome, then dimension reduction tools such as principal components analysis (PCA) [15] can
be used to produce a set of independent predictors from the original, highly correlated metabolites.
If, however, the interest is in the identification of important metabolites, then these tools can not be
applied and the original, correlated metabolites must be used. If the variables are extremely correlated
then identifying individual metabolites might be difficult without a huge sample size, but groups of
potentially important metabolites can be identified using the tools we discuss in the following section.
Within a given study sample, metabolite variation will be influenced by time-dependent factors
given that a portion of the human metabolome changes dynamically in response to acute perturbation
or stress while another portion of the metabolome exhibits relatively little change over time, except
in response to major chronic exposures. Further, the effects of metabolites on an outcome could
be influenced by confounding factors such as demographic variables or environmental exposures.
To account for this, the confounding factors must be adjusted for if the interest is in the effects of
particular exposures on an outcome. One such way to do this is to use a regression model that adjusts
for both the metabolite values and the confounding factors so that the metabolite effect is the effect
after conditioning on levels of confounding factors. Many of the approaches in the following section
can be adopted to adjust for confounding variables and should be done if the interest is in the effect of
a metabolite on an outcome.
3. Statistical Methods for Analyzing Metabolomics Data
A variety of different statistical methods are available for analyzing high-dimensional
metabolomics data. Many of these approaches are the same as those used with other omics based
data sources such as genomics, and a number of studies have looked to evaluate the performance of
some of these approaches in the context of high-dimensional omics data [16–19]. Methods that have
been applied in prior or ongoing clinical metabolomics studies are summarized in Table 2 and are
also described in more detail herein. We want to stress that the choice of statistical approach depends
heavily on the research question. Throughout, we will both explain the use of each method, as well as
discuss the types of research questions they can be used for.
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Univariate analyses with multiple testing correction, such as the Bonferroni correction for
controlling the global type I error rate or the Benjamini–Hochberg correction for controlling the false
discovery rate (FDR) [1], have previously been applied in a variety of predominantly metabolomics
targeted studies [2,3,20]. This approach involves M tests, where M is the total number of metabolite
variables analyzed separately in relation to an outcome of interest. The P value for each separate
metabolite test can be considered significant or non-significant based on a P value threshold that is
corrected to account for the fact that multiple hypotheses are being tested. The Bonferroni method is
commonly used and deems a metabolite significant if it is smaller than 0.05 / M, while other corrections
can be used to control the false discovery rate. Overall, univariate analysis with multiple testing
correction is an attractive approach because it is simple to implement and provides a measure of
statistical significance for each covariate that is easy to interpret. Further, it is very easy to adjust for
confounding factors when running univariate analyses as they can be included in a regression model
as additional predictors. However, this approach alone does not account for associations between
metabolites and outcomes that are conditional on other metabolite values. For instance, a given
metabolite may appear significantly associated with an outcome in isolation but does not demonstrate
a significant association when other metabolite associations are taken into account. Furthermore,
approaches to account for multiple testing, such as the Bonferroni correction or even FDR, can be very
conservative in the setting of a large number of analyzed metabolites, leading to limited statistical
power overall.
The principle components analysis (PCA) approach [15] is designed to reduce the dimension of the
number of metabolites being analyzed, assuming there is substantial correlation between metabolites
in a given dataset. Thus, PCA directly addresses the issue of intercorrelatedness and has been used
in prior human metabolomics studies, usually in combination with other methods [21–26]. The PCA
approach takes the original metabolites and finds linear combinations of these that are orthogonal to
each other and that explain the most variation in the metabolite dataset. The PCA approach can be
used to identify metabolite combinations associated with a given outcome, but PCA is not intrinsically
designed to identify original predictor variables (i.e., metabolites) of importance. A varimax rotation
can be used to increase the interpretability of principal components, given that principal components
are comprised of a small subset of the original metabolites [27], but this may not improve things greatly
with large numbers of metabolites. Those metabolites contributing to a given principal component
can be ranked by the importance of their contributions. However, for each contributing metabolite,
a measure of the magnitude of its association with given outcome is not provided, and a test of the
significance of association is also not provided. PCA can be used to show separation in two groups by
visually plotting their first and second principle components against each other [28], or can be used in
prediction modeling by reducing the dimension of the predictors [29]. Generally though, PCA should
not be used for identifying individual important predictors.
The partial least squares (PLS) regression method [30] aims to maximize the covariance between a
matrix of metabolites and a continuous outcome (or categorical outcome using the PLS discriminant
analysis (DA) variation [31]) by decomposing metabolite and outcomes data into latent structures. Cross
validation can be used to select the optimal number of latent variables that are used. This approach
aims to maximize the covariance between the outcome and matrix of metabolites by projecting both to
linear subspaces of the original variables. There has been widespread use of PLS in metabolomics
studies [21–24,32–35], although it comes with some limitations with regard to metabolite selection.
While finding reduced dimensions that can explain the outcome variable, PLS regression generally
provides only a measure of variable importance and does not naturally perform variable selection,
although a number of ad hoc approaches for variable selection have been proposed [36,37]. Nonetheless,
no clear-cut approach is best for determining which metabolites are actually important in predicting
the outcome. Sparse extensions of both approaches have been proposed [34,38–41], which add a
penalty to the loading scores forcing some of the variables to have zero weight in the final model.
One can take the list of non-zero metabolites to be the metabolites that are deemed important. This
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is potentially a very fruitful direction for identifying important metabolites that jointly predict the
outcome well. The resulting set of variables can be substantially different from the variables selected
by univariate methods that analyze each metabolite separately. To this end, multivariate PLS methods
can be implemented using the SPLS package in R [39].
The linear discriminant analysis (LDA) approach has also been used in metabolomic studies
and aims to find linear combinations of metabolite variables that are best able to separate classes
of a categorical outcome [25,26]. Although LDA cannot be used for a continuous outcome, such an
outcome may be discretized for the application of LDA. Conventionally, LDA will perform poorly
or can even fail completely when the number of covariates exceeds the number of subjects [42,43], a
common feature of metabolomics datasets. One could use principle components first and then run
discriminant analysis; however, this approach will suffer from the same interpretational problems as
PCA by not allowing for identification of important metabolites. Furthermore, the LDA approach does
not intrinsically identify a set of important variables and can only be used to create variable rankings or
importance measures. For this reason, we consider a sparse version of LDA [44–46], which again adds
a penalty for the variable loadings and, thus, allows for simultaneous variable selection. As with PCA
and PLS, LDA can provide a measure of variable importance that can be used for metabolite ranking.
The least absolute shrinkage and selection operator (LASSO) approach aims to fit a model that
regresses the outcome against all of the metabolites simultaneously and applies a penalty to the
magnitude of regression coefficients to achieve sparse variable selection [47]. Traditional regression
models are not infeasible when the number of metabolites is larger than the sample size [48], since the
model becomes overfit and the parameter estimates become meaningless. To address this issue, the
LASSO applies a penalty to the magnitude of the regression coefficients, which forces the regression
coefficients for many coefficients to be zero while also shrinking others in magnitude. LASSO has been
shown to be useful in both prediction and metabolite selection [49,50]. One can take the collection of
metabolites with non-zero regression coefficients from LASSO to be “significant” in the sense that they
are associated with the outcome. This should not be confused with statistical significance in the general
sense of P values and rejecting null hypotheses; however, it is a powerful tool for variable selection. To
perform LASSO, one must also select a tuning parameter for the penalty; however, this can be done
via cross validation. LASSO has many desirable large sample properties including model selection
consistency, which states that one can select the proper metabolites with probability tending toward
the value of 1.0 if we have enough data. LASSO is known, however, to struggle in small samples with
highly correlated covariates as it will simply choose one among the group of correlated variables and
force the others to be zero. In these cases, related methods such as elastic net, which is a compromise
between the LASSO and ridge regression procedures, can be utilized as well. These methods should
provide the user with a set of metabolites that are associated with the outcome conditional on the
other metabolites. Again, this may differ substantially from the variables identified by univariate
techniques that do not look at conditional associations. Further, confounding factors can easily be
incorporated into these high-dimensional models by including them as predictors and ensuring that
their parameters are not penalized or shrunk to zero. LASSO and its variants can be implemented in
the glmnet package in R [51].
Random forests is a non-parametric ensemble method that prioritizes prediction by attempting to
find non-linear patterns in metabolites that can explain variation in a given outcome [52]. Random
forests are very powerful tools if the relationships between the metabolites and the outcome are
complex and non-linear, and has been used for both missing data imputation and outcome analysis in
metabolomics [11,53]. One drawback of this approach is that, similar to PCA, it does not provide a
measure of statistical significance or provide any p-value or equivalent quantity. Metabolite importance,
however, can be assessed by removing metabolites one at a time, re-running the procedure, and seeing
how much predictive capability was lost. This provides the analyst with a list ranking the most
important metabolites but does not provide a cutoff for which metabolites are significant. Random
forests can be implemented in either the randomForest or H2O packages in R [54,55].
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Table 2. Statistical analysis methods for outcomes analyses of human metabolomics data.
Method Univariate orMultivariate
Handling
Binary
Outcome
Handling
Continuous
Outcome
p Value for
Significant
Metabolites
Metabolite
Selection Advantages Disadvantages
Multiple tests (e.g., univariate linear
regression) with
Bonferroni correction
Univariate Yes Yes Yes Yes Simple, easy to use andinterpret results
Very conservative and does not account
for intercorrelation
Multiple tests with false discovery
rate (FDR) Univariate Yes Yes Yes Yes
Simple, easy to use, less conservative
than Bonferroni correction
Does not account for intercorrelation
among features
Principal component analysis (PCA) Multivariate Yes Yes No No Effective for variable reduction No intrinsic clarity on how to select orrank variables
Sparse partial least squares (SPLS) Multivariate No Yes No Yes Can quickly find a subset of variablesthat predicts the outcome well
Multiple tuning parameters are needed to
be chosen via cross validation
Linear discriminant analysis (LDA) Multivariate Yes No No Yes Simple and works forcategorical outcomes Can not handle large numbers of features
Least absolute shrinkage and
selection operator (LASSO) Multivariate Yes Yes No Yes
Can quickly find a subset of variables
that predicts the outcome well
May not perform well for metabolite
selection when the features are
highly correlated
Random forests and other machine
learning approaches Multivariate Yes Yes No No
Can find complex relationships
between variables
If data is truly linear, this will be
less efficient
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Additionally, there is a vast array of methods in the machine learning literature that provide very
flexible models for handling data with a large number of covariates. These approaches are appreciably
powerful tools for predicting a given outcome of interest although, in many cases, at the expense of
the interpretability of the resulting models. Examples of commonly used approaches include support
vector machines (SVM), neural networks, and the previously mentioned random forests [56,57]. All of
these methods are subject to many of the same limitations, as discussed for random forests, in that they
can provide a variable importance measure but do not provide a set of variables that can be thought of
as statistically significant.
A note regarding sparsity in statistical methods is warranted. A general problem of many
approaches that may be used to analyze metabolomics data is that they do not easily result in a final
list of “top hit” metabolites associated with a given outcome of interest. Instead, they are useful for
providing heuristic measures that indicate variable importance and, in doing so, do not eliminate
clinical or other covariates from the model of total covariates included in analyses. For this reason, we
recommend focusing on sparse alternatives to statistical methods because, as discussed above, they
are intended to directly address this issue. In this context, sparsity is based on the assumption that
the number of true positives is limited, such that the contribution to variation in an outcome can be
defined by a set number of non-zero values for a set number of coefficients, with the remaining being
zero values. One of the most naive ways to achieve a sparse result, for instance, would be a stepwise
(e.g., forward) selection, but alternate methods are preferred when the number of metabolites is far in
excess to the number of observations.
4. Metabolomics Statistical Analysis Workflow
In addition to considering which statistical methods to apply in relating curated metabolomics
data to clinical outcomes, a series of study design and data management steps are required as part of a
complete analytical workflow. While not intended to be comprehensive, an overview of these steps is
provided below. All examples of data analysis provided are derived from real clinical or epidemiologic
cohort data unless otherwise specified.
4.1. Study Design
Prior to beginning any experiment, all aspects of study design should be carefully considered.
This process includes many considerations. First, the choice between univariate vs. multivariate
methods is largely driven by the scientific question of interest. If the primary objective of the study is
to identify all metabolites associated with a particular outcome, the univariate methods preferable.
If the primary objective instead is to utilize potentially multiple metabolites to predict the outcome
of interest, then multivariate methods will be preferred. Next, a decision on whether metabolite
predictors of a given outcome will be investigated in a case-control (and, if so, the number of cases and
controls), a case-cohort, or total cohort design. In this step, it is critically important to consider the
number of outcome occurrences (i.e., cases) available for analysis and the anticipated effect size for
metabolomic variation in relation to case status. For example, for a rare outcome (i.e., 1% prevalence in
the study population), there is greater statistical power to detect a given effect size via a case-control
study design of n = 42 (21 cases vs. 21 controls) than via an unselected sample of n = 1000 (10 cases
vs. 990 controls). Also, it is necessary to decide on whether the metabolomics profiling method to be
used will be nontargeted or targeted and, if targeted, the type of targeted approach. This decision will
impact the approximate number of metabolites that will be measured. Taken together, information on
the total number of observations, frequency or distribution of outcomes, and number of metabolites
measured will determine the extent to which the experiment will be adequately powered for detecting
clinically significant associations of interest. As an example, when using Bonferroni-like approaches to
control type-I error, the difference between testing 200 vs. 2000 metabolites results means comparing
the results of statistical tests against p-values of 0.00,025 (=0.05/200) vs. 0.000,025 (=0.05/2000). A study
designed to detect a given magnitude of association with conventional 80% power for the former
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would have only 60% power in the latter scenario due to the more stringent threshold for declaring
statistical significance. As a result, the magnitude of the minimal association that the latter study
would be able to detect would be approximately 15% greater than originally planned and the sample
size would need to be increased by 30% in order to regain sufficient power to detect the originally
intended magnitude of association. Similar considerations are needed for the analysis of continuous as
opposed to binary outcomes. For a normally distributed outcome, the sample size required to detect a
difference between groups will be at least 50% larger if the outcome is first dichotomized and analyzed
as binary rather than continuous. Overall, this step is essential for conducting analysis of metabolomics
data wherein the number of metabolites measurable typically far exceeds the number of individuals
studied within a given experiment.
4.2. Data Management
It is becoming increasingly recognized that several key data management steps are extremely
important for ensuring not only the integrity but also feasibility of metabolomics data analysis. For
instance, it is always important to perform a careful assessment for batch-to-batch variability that
can often persist even after preprocessing steps have been successfully completed (e.g., for alignment
of mass spectral features) [58]. While an area of ongoing research, informed decisions can be made
regarding whether or not to normalize a given dataset to internal standards, to pooled plasma measures,
to both, or to neither [59–61].
All datasets should be examined for their data structure, including the distribution and type of
missingness across metabolites and across individuals. Different approaches to handling missingness
may be suitable depending on the types of metabolites profiled (e.g., known to be rare, low abundant, or
technically difficult to detect). As discussed in Section 2, imputation strategies are generally preferred
to more ad hoc approaches such as simply filling in missing values as zero or half the minimum
observed values. Subset analyses are always possible, and some investigators have elected to exclude
analytes with substantial missingness from all analyses. All approaches to handling missing values
may introduce bias, depending on the method and cohort characteristics. While we have provided
suggestions in Section 2, we also feel that sensitivity analysis is crucial to ensure that the results are
robust to the chosen method for addressing missingness. Researchers should look at their primary
research question and evaluate whether their conclusions change substantially across differing methods
for missing data. After having addressed issues related to missingness, metabolite variables typically
benefit from applying transformation and scaling to allow for appropriateness and comparability
of statistical analyses (Figure 1). Although natural log transformation is commonly used for most
or all metabolite variables in a given dataset, given the typical high proportion of metabolites with
right-skewed distribution, this approach may not be optimal for all variables [14]. We recommend
performing a natural log transformation of all metabolite variables and then assessing the skewness
before and after transformation. For those metabolites for which the skewness is not improved after
transformation, we recommend retaining the original untransformed variables for further analysis,
with transformed values used for the other metabolites. While standardization of transformed variables
is also commonly used, so that magnitudes of effect are comparable across models, other approaches
such as Pareto or level scaling may be more appropriate for certain study designs (i.e., taking into
consideration the main research questions and outcomes of interest) [14].
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Figure 1. Metabolite data transformation and centering. A frequently used approach for managing
metabolite data collected in a large human cohort study involves log transforming each metabolite
measur s and ce tering the data on plate median to account for batch to atch vari tion. Interestingly,
variable transform tion can reveal multi-modal distributions.
4.3. Optional Simulation Analyses
If feasible, an ideal approach is to dev lop a dataset that si t e design, size, and features of
the study at hand, inclu ing the umber of metabolites measured an the expected or known number
of outcomes. Simulated data allow for comparisons of performance of the different statistical methods,
so that the most optimal method can be selected for a given study. Simulations are especially useful
for guiding the design of studies that are in the early planning phases, particularly those for which
the number of metabolites and the number of study subjects are yet to be determined. To perform
such simulations in a relevant manner, some data structural features of the data must be known. For
instance, if prior data are already available, the empirical distribution of the metabolites can be used
(Figure 2). One can resample the rows of he true data to obtain si ulated data that clo ely replicate
the true data, and then an outcome can be generated assuming a pre-specified relatio ship w th the
metabolites. Another possibility is to learn the covariance matrix among all the metabolites in the study
and then draw values from a multivariate normal distribution with this covariance to create simulated
metabolite variables. If an example of true data is not available and simulations are being used to
design a new study, then a dataset from previously conducted related study may be used to guide
the simulation design. With simulated datasets in hand, it is possible to obtain power calculations
that are relevant and applicable for planning study design. One can simulate metabolites and an
outcome and repeat this process many times over while recording the percentage of times a metabolite
marker of interest is identified, which provide the power at the given sample size. This process can be
performed i eratively using different sample sizes, and different pre-specified associations between the
metabolites and outcome, to gain a better understanding of the power available to identify signals in
the planned study.
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Figure 2. Actual and simulated metabolo i s t . Previously nalyzed data, or prior detailed
knowledge of the structure of metabolomics data collected from an existing large epidemiologic cohort
study (a) can be used to construct simulated data that mimics the data structure observed from real
measures (b). These simulated data can be used to estimate statistical power, based on one or more
methods of analyses, for planning the design of a future study.
4.4. Cross-Sectional or Prospective Analyses (i.e., Outcomes Analyses)
After selecting the most appropriate statistical approach, based on prior experience or the results
of simulation analyses (Section 4.3 above), applying a method that includes internal cross-validation
should be considered. Cross-validation procedures are intended to optimize generalizability and reduce
variability of results by performing repeated analyses on different partitions of the dataset and then
averaging the results to estimate a final model. For instance, in k-fold cross-validation, the total dataset is
randomly divided into k equally ized subsets, a d k-1 subsets are analyzed while reserving different
single subset for validation during each iteration. An alternative to cross-validation is conventional
validation or dividing the original dataset into training and validation subsets (e.g., 2/3, 1/3) while
assuming the original dataset size is large enough to accommodate this approach and a separate validation
cohort is not available. Yet another option for assessing generalizability is to apply other statistical
methods and compare results [62], as an investigator can feel more confident about results that are
consistently obtained irrespective of the statistical technique used (see Section 4.4 below). It should be
noted that this only ens res the robustness to the choice of statistical approach, but does not guarantee
accuracy of the results. There are number of issues in the coll ction and pre-processing f data that
could lead to systematic errors, a d no st ti tical approach ca correct for hese. In th e cas s, the
statistical approaches might all lead to the same, but incorrect, answers. For this reason, it is crucial to
carefully design the study and assess the robustness of all stages of the workflow.
4.5. Real-Life Application of Multiple Statistical Methods
Herein, we r vide n example of how data analys s results can v r hen fferent statistical
modeling approaches are applied to real-life metabolomics data. Specifically, we studied N = 1497 adult
participants of the Framingham Heart Study Offspring cohort (age 67 ± 10 years, 55% women) who had
fasting plasma collected at their eighth examination [63]. We used a direct nontargeted mass spectrometry
profiling method [64] to quantify P = 547 metabolites of the eicosanoid family (a subset of bioactive lipids)
in the collected plasma samples. These metabolites included eicosanoid species that are known to be
predominantly derived from eicosapentaenoic acid (EPA) (20:5, n-3) and docosahexaenoic acid (DHA) (22:6,
n-3), each of which hs been linked to a variety of clinically important cardiometabolic traits [65]. The extent
to which specific eicosanoids (as potential derivatives) are more or less related to EPA versus DHA (as
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potential initial substrate molecules) has not be clarified, and so we used different statistical modeling
approaches to identify and prioritize eicosanoids of interest. As shown in Figure 3, different modeling
methods produced distinct results. We observed relative consensus in results between the univariate
approaches and the random forest approach, and among the multivariate approaches, but less so across
these groups of methods. Intrestingly, univariate and random forest approaches tended to select metabolites
within one intercorrelated group, and multivariate approaches tended to select metabolites across multiple
clusters of intercorrelated metabolites (positive correlations shown in red; negative correlations shown in
blue). Notably, the top metabolites from the univariate approaches are all highly correlated, suggesting that
multivariate approaches are selecting metabolites after conditioning on the other predictors, which likely
contributes to the observed variability in results. Additionally, discordant results likely reflect different
assumptions and features between methods, such as the assumption of linearity of association between
a predictor and outcome for conventional regression models, which random forests does not rely on.
These findings highlight the potential for multivariate methods, by contrast, to select putative orthogonal
rather than common pathways of biological interest. In this particular example, the distinction is relevant
for identifying potential eicosanoid pathways that may be enriched versus diversified with respect to their
reliance on either EPA or DHA metabolism and their downstream effects—which are likely to be similar to
each other in some respects and different in others [65].
Metabolites 2019, 9, x 12 of 16 
 
and docosahexaenoic acid (DHA) (22:6, n-3), each of which hs been linked to a variety of clinically 
important cardiometabolic traits [65]. The extent to which specific eicosanoids (as potential 
derivatives) are more or less related to EPA versus DHA (as potential initial substrate molecules) has 
not be clarified, and so we used different statistical modeling approaches to identify and prioritize 
eicosanoids of interest. As shown in Figu e 3, different modeling methods produced distinct results. 
W  observed elative cons nsus in results between the univariate appro ches nd the random f rest 
approach, and among the multivariate approaches, but less so across these groups of methods. 
Intrestingly, univariate and random forest approaches tended to select metabolites within one 
intercorrelated group, and multivariate approaches tended to select metabolites across multiple 
clusters of intercorrelated metabolites (positive correlations shown in red; negative correlations 
shown in blue). Notably, the top metabolites from the univariate approaches are all highly 
correlated, suggesting that multivariate approaches are selecting metabolites after conditioning on 
the other predictors, which likely contributes to the observed variability in results. Additionally, 
discordant results likely reflect different assumptions and features between methods, such as the 
assumption of linearity of association betw en a predictor and outcome f r conventional regression 
models, which random forests does not rely on. These findings highlight the pot ntial for 
multivariate methods, by contrast, to select putative orthogonal rather than common pathways of 
biological interest. In this particular example, the distinction is relevant for identifying potential 
eicosanoid pathways that may be enriched versus diversified with respect to their reliance on either 
EPA or DHA metabolism and their downstream effects—which are likely to be similar to each other 
in some respects and different in others [65]. 
 
Figure 3. Using multiple statistical methods to evaluate results in a real-life application involving 
analyses of large cohort metabolite data. We related a panel of bioactive lipid molecule metabolites 
(i.e., eicosanoids) to putative derivative substrates (i.e., eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA)), which were considered in all analyses as the outcomes of clinical 
relevance and interest. We used multiple different statistical methods and compared results. 
Metabolites are denoted by mass-to-charge (m/z) ratio and retention time (rt, in minutes) using the 
Figure 3. Using multiple statistical methods to evaluate results in a real-life application involving analyses
of large cohort metabolite data. We related a panel of bioactive lipid molecule metabolites (i.e., eicosanoids)
to putative derivative substrates (i.e., eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)),
which were consid red in all analyses as the outcomes of clinical relev nc and interest. W used multiple
different statistical methods and compared results. Metabolites are denoted by mass-t -ch rge (m/z) ratio
and retention time (rt, in minutes) using the m/z_rt convention, and are listed in rank order for each
outcome (EPA or DHA) according to performance metrics provided by each model.
4.6. Prioritization of Results for Follow-Up Investigations
When using a nontargeted MS method, the majority of significantly associated metabolites will
invariably be novel (i.e., previously unidentified molecular species). Thus, an imperative next step in
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the scientific process is to identify such novel molecules of potential clinical importance. However,
the process of identifying the specific chemical structure of a previously unknown small molecule
is time-consuming and potentially very resource-intensive, depending on the molecule’s relative
abundance in available biospecimens and other characteristic features. Therefore, the results of
statistical analyses should ideally be robust and convincing before they are used to direct efforts made
towards novel small molecule identification. To this end, several statistical approaches to prioritizing
small molecules for follow-up identification are possible. Univariate approaches and p-values provide
a simple and effective tool for prioritizing metabolites that are associated with an outcome. We
have discussed how other approaches based on high-dimensional models can lead to another set
of important metabolites that are important for predicting the outcome when conditioning on other
metabolite values. These multivariate approaches can be quite useful when the metabolites are highly
correlated, though may only select one out of a group of highly correlated variables associated with an
outcome. Understanding the differences between these prioritized variables is crucial and the choice
of which to use depends on the research question of interest. Beyond cross-validation or conventional
validation within a dataset, external replication in a separate cohort is ideal, and even further value
can be gained from using different metabolomics platforms [8]. In addition, confirmatory results from
performing different types of statistical analyses (e.g., traditional and non-traditional) in both training
and validation cohorts may be informative.
5. Conclusions
High-throughput metabolomics data provide an exciting area of research for scientific discovery,
but they are accompanied by a number of statistical challenges that must be properly addressed to
infer meaningful results from such complex data. Herein, we have reviewed and outlined practical
solutions for many of the common problems found in metabolomics data analysis. While outlining
some guidelines for future researchers on how to address these issues, the optimal solution at any
given stage of data management and analysis depends on the size and design of the specific data
and study at hand, as well as the research questions being addressed. Thus, a critical aspect of any
analysis is explicit recognition of the strengths and weaknesses of the selected approaches as well as a
complete understanding of the assumptions that are implicit for every decision made at each step of
the analysis workflow. Many important decisions, such as those related to handling of missing data
and transforming skewed data, can have substantial and meaningful impacts on the final analysis
results. Therefore, we recommend that researchers perform sensitivity analyses with respect to such
decisions to assess the robustness of their results in the context of such subjective choices. In addition,
any findings from primary analyses should be replicated in additional studies to confirm their potential
to serve as meaningful scientific findings, irrespective of the statistical decisions made.
While we have reviewed potential solutions for the problems that are often encountered in human
metabolomics studies, many of these issues do not have definitive answers, and this presents many
possibilities for future methods research that can aim to improve decision making at each stage of the
analysis workflow. These are all open areas of research, and finding optimal solutions will lead to
substantial improvements in analysis, reproducibility, and overall contributions in the field of human
metabolomics investigation.
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